ERBB2 and breast cancer: The ADAPT-TP trial was a phase II study comparing 12 weeks of neoadjuvant T‐DM1 with T‐DM1 plus endocrine therapy and trastuzumab plus endocrine therapy in 375 luminal B/HER2-positive early stage BC patients.